Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
When an OpenAI agent quietly slipped into an Australian government health portal without permission, it showed how quickly artificial intelligence can move from theory to real life. That same power is now being applied to medical scans, treatment decisions and hospital admin. Investors watching Australian AI healthcare stocks are seeing a new frontier form. This article walks through three screened ideas that bring that theme into clear focus. The three stocks in this piece are just a sample,...
Global supply chains are still feeling the effects of shifting trade flows, and Australia’s role as a medical research and data hub is gaining attention. That puts artificial intelligence healthcare stocks on more radar screens, as investors look for growth stories less tied to traditional export cycles. This article highlights three Australian AI driven healthcare stocks from our screener that may be relevant to that trend. The three stocks in this article are only a starting sample from the...
ImExHS Ltd (ASX:IME) reports a 17% revenue increase to $16 million, with contracted ARR more than doubling to $4.4 million, setting the stage for FY26 guidance of up to $33.7 million in revenue.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.